Insulet Corp (PODD) reported third-quarter earnings for fiscal 2025, surpassing analyst expectations. The company's earnings per share (EPS) reached $1.24, exceeding the consensus estimate of $1.16 by $0.08. Revenue for the quarter matched expectations at $0.7 billion.
The announcement highlights Insulet's continued operational strength in the health care sector. The company, headquartered in Acton, Massachusetts, specializes in the development and marketing of insulin infusion systems for individuals with insulin-dependent diabetes. Insulet's Omnipod System, which includes the Omnipod 5 Automated Insulin Delivery System, provides a tubeless insulin delivery solution without the need for external tubing.
Insulet is scheduled to host an earnings conference call to discuss these results and provide further insights into its business performance.
As of November 8, 2025, the company has a market capitalization of $22.76 billion and a trailing twelve-month price-to-earnings (P/E) ratio of 96.42. Looking ahead, analysts estimate an EPS of $1.41 and revenue of $0.8 billion for the upcoming earnings report on August 4, 2026.